NEW YORK (TheStreet) -- PlasmaTech Biopharmacueticals (PTBI) shares are up 4.14% to $8.31 in morning trading on Monday after the Dallas-based pharmaceutical company had coverage initiated with a "buy" rating by analysts' at H.C. Wainwright before the opening bell today.
The firm also placed a $15 price target on the company's shares, representing a potential 80.5% upside from the stock's current price.
"PlasmaTech's core platform is centered on salt diafiltration (SDF) technology for the isolation of plasma proteins, including (but not limited to) AAT and intravenous immunoglobulin (IVIG). This SDF process offers significant optimization in AAT production yields and costs (~10x), and could easily enable more competitive pricing, and poach market share in this orphan indication," said analyst Andrew S. Fein.
"Overall, we believe that as the SDF platform begins to move through manufacturing validation and characterization in the next few months, the company is likely to come into the focus of investors and partners alike, with shares continuing on an upwards trajectory reflective of the potential of the AATD orphan market," Fein continued.
- You can view the full analysis from the report here: PTBI Ratings Report